Another strategy developed to inhibit EGFR is the usage of monoclonal antibodies such as trastuzumab and cetuximab, which can control the growth of breast cancer cells overexpressing human epidermal growth factor receptor 2 (HER2). The gene discussed is ERBB2; the disease is breast cancer.